Our Pro-inflammatory Cytokine Panel Screening Service provides an advanced platform for studying the role of pro-inflammatory cytokines in disease pathogenesis, particularly in autoimmune disorders, cancer, and chronic inflammatory conditions. Numerous disorders are linked to the dysregulation of cytokines, which are important regulators of immunological responses. By identifying and profiling pro-inflammatory cytokines, this service helps researchers discover novel therapeutic targets, identify biomarkers for disease progression, and evaluate potential drug candidates that modulate cytokine activity.
Pro-inflammatory cytokines are small signaling molecules secreted by various immune cells, including macrophages, T-cells, and dendritic cells. These cytokines play pivotal roles in modulating immune cell recruitment, activation, and tissue inflammation. Key pro-inflammatory cytokines include:
The dysregulation of pro-inflammatory cytokine production can drive chronic inflammation and contribute to tissue damage, making these cytokines important targets for therapeutic interventions.
Our Pro-inflammatory Cytokine Panel Screening Service offers a comprehensive approach to evaluate the impact of compounds on the production, release, and signaling of key pro-inflammatory cytokines.
Our panel includes a wide range of cytokines relevant to inflammatory and autoimmune diseases, including TNF-α, IL-1β, IL-6, IL-17, IFN-γ, and others. We assess cytokine levels in cell culture supernatants or serum/plasma samples from animal models to provide a comprehensive cytokine profile.
We simulate the immune response using immortalized cell lines and human primary immune cells, including T-cells, dendritic cells, and macrophages. These assays allow us to evaluate:
Cytokine production: Quantify the release of pro-inflammatory cytokines in response to stimuli (e.g., LPS, TNF-α).
Cytokine expression: Measure the expression of cytokine mRNA or protein levels using quantitative PCR (qPCR), ELISA, or multiplex assays.
Cell activation and proliferation: Assess the activation of immune cells, such as macrophages or T-cells, by measuring markers like CD69, CD25, or intracellular cytokine staining.
The service supports the screening of compound libraries to identify inhibitors or modulators of pro-inflammatory cytokine release. Compounds are tested for their ability to modulate cytokine secretion, either inhibiting excessive cytokine production or enhancing cytokine release in therapeutic settings.
We can carry out other tests to ascertain your compounds' mode of action, such as:
Pathway analysis: Investigate the signaling pathways involved in cytokine release (e.g., NF-κB, MAPK, JAK-STAT pathways).
Gene expression profiling: Use RNA-seq or qPCR to explore how compounds affect gene expression in immune cells.
Depending on your research needs, we can customize the panel to include additional cytokines or to focus on specific diseases, such as cancer, autoimmune disorders, or infectious diseases.
A1: We screen a variety of compounds, including small molecules, biologics (e.g., monoclonal antibodies, cytokine inhibitors), peptides, and natural products. Our service is highly adaptable to different types of drug discovery efforts.
A2: Our main area of interest is immune cell culture-based in vitro tests. However, we also support in vivo studies using animal models for more complex evaluations of compound efficacy in modulating inflammation.
If you're interested in learning more about our Pro-inflammatory Cytokine Panel Screening Service or would like to discuss your specific research needs, our team is ready to assist you. We can help you optimize your screening process, identify key therapeutic targets, and provide expert support throughout your drug discovery journey. Let us help you discover novel therapeutic agents by modulating the immune response with our advanced Pro-inflammatory Cytokine Panel Screening Service!